【レポートの概要（一部）】
1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2016-2026
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014 and 2015
3.3 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025
4. Leading National Markets for Companion Diagnostics, 2016-2026
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
4.2.1 Changing Market Shares of Leading National Markets, 2016-2026
4.3 The US Companion Diagnostics Market Sales Forecast, 2016-2026
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2016-2026
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2016
7. Leading Companies in the Companion Diagnostics Market 2015
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.8.1 Ventana/Genmab
7.1.8.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.8.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.6 Boehringer Ingelheim/Roche
7.1.8.7 ImmunoGen/ Ventana
7.1.8.8 Foundation Medicine/Roche
7.1.9 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
7.1.9.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
7.1.9.2 IQuum Acquisition Allows Movement into POC MDx Market
7.1.9.3 Seragon Acquisition Strengthens Leading Position in Oncology
7.1.9.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
7.1.9.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
7.1.9.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
7.1.9.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
7.1.9.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
7.1.9.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
7.1.9.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2010-2015
7.2.2 Qiagen Sales By Region
7.2.3 Companion Diagnostics Collaboration Agreements with Pharma, 2015
7.2.3.1 Collaboration with Eli Lilly
7.2.3.2 Collaboration with AstraZeneca
7.2.3.3 Collaboration with Astellas Pharma
7.2.3.4 Collaboration with Novartis
7.2.3.5 Collaboration with Array BioPharma
7.2.3.6 Collaboration with Protagen
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2012-2015
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity and Collaborations
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.3.3.3 Collaboration with AstraZeneca
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.4.4.3 Agilent/Bristol-Myers Squibb
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.5.4.4 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2010-2015
7.6.2 Sales by Region, 2014
7.6.3 Sales by Technology, 2015
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Collaboration with Gilead Sciences
7.6.4.2 Collaboration with Ipsen
7.6.4.3 Collaboration with Merck
7.6.4.4 Collaborations with GSK and Novartis
7.6.4.5 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2013-2014
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2015
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Acquisition of Life Technologies
7.7.2.2 Acquisition of Prionics
7.7.2.3 Acquisition of Advanced Scientifics, Inc.
7.7.2.4 Acquisition of Alfa Aesar
7.7.2.5 Affymetrix: Thermo Fisher’s Next Target
7.7.2.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.7.2.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
7.7.2.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
10. Glossary
Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：コンパニオン診断（CDx）の世界市場予測2016-2026■ 英文：The Companion Diagnostics (CDx) Market Forecast 2016-2026
■ 発行日：2016年3月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041538
■ 調査対象地域：グローバル
- GermanyのSewing Thread of Manmade Filaments市場：貿易（輸入、輸出）動向This market research report examines the foreign trade of Germany and its perspectives on the global market for Sewing thread of manmade filaments. The report will be of considerable interest primarily to relevant strategic planners, senior company officials and importers/exporters, since it features invaluable information on Sewing thread of manmade filaments export/import operations in Germany. …
- 世界のクラウド型ストーレジ市場動向（2012-2016）TechNavio's analysts forecast the Global Cloud-based Storage market to grow at a CAGR of 36.41 percent over the period 2012-2016. One of the key factors contributing to this market growth is the rapid increase in the adoption of tablets and smartphones. The Global Cloud-based Storage market has also been witnessing the increasing number of vendors leading to decreasing costs. However, the growing …
- 電子産業向け化学品・材料の世界市場：ウェハー、雰囲気ガス・特殊ガス、補助化学品、光レジスト化学品、化学機械研磨（CMP）スラリー、湿式処理用化学品About Electronic Chemicals and Materials High-purity chemical, gases, and materials are used during the fabrication of printed circuit boards (PCBs), electronic semiconductors, liquid-crystal displays (LCDs), ICs, and light emitting diodes (LEDs), which are used in electronic devices. The rising demand for advanced electronic devices that can offer high-speed functionality with efficient heat diss …
- エンコーダーの世界市場予測（～2024年）“Encoders market to grow at significant rate from 2019 to 2024” The encoders market is expected to grow from USD 1.6 billion in 2019 to USD 2.4 billion by 2024—at a CAGR of 8.6%. Key factors driving the growth of the encoders market include the need for high-end automation and industry 4.0. Strategies such as product launches adopted by market players are fueling the growth of the encoders market. …
- 半導体製造用材料の世界市場：シリコンウェーハ、フォトマスク、フォトレジスト、湿潤化学物質、CMPスラリー/パッド、ガス、スパッタターゲット材Technavios research analyst predicts the global semiconductor fabrication material market to grow steadily at a CAGR of around 4% during the forecast period. The growth of the global semiconductor industry is the primary growth driver for this market. The rising demand for high-performance devices with improved speed and capacity has positively impacted the demand for silicon, reflective coating, …
- 農業用微量栄養素の世界市場：亜鉛、ホウ素、銅、マンガン、モリブデン、鉄The market size is projected to reach USD 8.05 Billion by 2021, growing at a CAGR of around 8.2% from 2016. The global agricultural micronutrients market has grown exponentially in the last few years. Countries in the Asia-Pacific region such as China, Japan, and India are the primary targets of the industry. Increase in soil deficiencies, macronutrients antagonism, and increasing demand for of hi …
- パドルスポーツ用品の世界市場2017-2021ABSTRACTAbout Paddlesports Equipment The global paddle sports equipment market includes rafting, standup paddle boarding, and canoeing and kayaking equipment. The market is expected to grow due to the advances in technology, which improve the features of these products, thereby enhancing their performance. Technavio’s analysts forecast the global paddlesports equipment market to grow at a CAGR of …
- The Apple iPad: New Standard for Mobile Computing & Wireless ExpectationsThe Apple iPad is an innovative computing tablet that is expected to cause a substantial ripple in information technology in the area of notebooks and wireless communications. Its allure lies in its technological innovations, purported to provide the ultimate web and computing experience in a simple, portable package. Brand loyalty among Apple customers will certainly make up the bulk of initial s …
- 世界のポータブル医療機器市場：心臓、呼吸、血行、健康機器などMobile healthcare market means Portable (movable/compact) healthcare products with integrated wireless communication capabilities (using various types of WLAN, WPAN and WMAN technologies with different protocols). These products are generally used for measuring & monitoring data in combination with display or representation of the data on a mobile computing device, typically a smart-phone or a tab …
- グローバルにおけるHDTV市場（2014-2018）About HDTV The HDTV is a next generation television equipped with better resolution and high quality display. It is based on a digital broadcasting format that transmits a widescreen display, enlarged and clear image, better sound quality and projections. According to the EIA, high definition in TV can be measured by the resolution of the picture or the number of horizontal and vertical lines scan …
- ニトリルブタジエンゴム（NBR）粉末の世界市場：製品別（直鎖、架橋）、用途別（PVC改質、自動車、建設）、セグメント予測The global nitrile butadiene rubber powder market size is expected to reach USD 586.0 million by 2025, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 5.8% during the forecast period. Cross-linked NBR is likely to witness the fastest growth, on account of increasing usage of the product in consumer goods and PVC modification sectors. Nitrile rubber pow …
- 世界の主要な廃棄物エネルギー転換（WtE）企業分析2015Visiongain’s report analyses the 25 leading operators of waste-to-energy plants in the 244 million tonnes per annum global market. The leading players comprise a diverse range of companies, including international utilities, national agencies and devolved bodies, and smaller engineering, procurement and construction (EPC) and operations and maintenance (O&M) companies. Most of the operators have e …
- アジピン酸の世界市場ABSTRACTAbout Adipic Acid Adipic acid is a dicarboxylic acid with a white crystalline structure. It is produced from benzene by first converting into ketone-alcohol oil and then oxidizing it with nitric acid. It is partially soluble in water but is completely soluble in alcohol and acetone. It is also produced by various other processes such as carbonylation of butadiene, phenol-based production, …
- アジアの風力発電産業分析：Analyzing the Asian Wind Power IndustryGlobal demand for energy is increasing at a breathtaking pace, and this is particularly true in China, India and other rapidly developing economies. However, as demand on finite petroleum reserves and the price of the fuels derived from them continues to rise, renewable forms of energy are becoming more cost-effective and profitable. In the forefront of this renewable revolution is harnessing the …
- MEMS発振器の世界市場About MEMS Oscillators MEMS oscillators are designed and developed to replace the established quartz crystal oscillators. MEMS oscillators are timing devices that have several advantages over quartz crystal oscillators. Better reliability, higher frequency stability, mechanical shock and vibration resistance, and smaller in size are features that are highly suited for several end-products that req …
